Active-ingredient Dossier
Omeprazole
Active-ingredient Dossier for Omeprazole (proton pump inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: LOSEC
- Brand: MAXOR
- Brand: ACIMAX
- Brand: APO-OMEPRAZOLE
- Brand: OMEPRAL
- Brand: OMEPRAZOLE
- Therapeutic area: Gastroenterology
What is
Omeprazole Omeprazole is a proton pump inhibitor.
Australian brands containing
Omeprazole — MAXOR — PROBITOR — APO-OMEPRAZOLE — OMEPRAZOLE — OMEPRAZOLE ADVZ — OMEPRAZOLE-WGR — OMEPRO-GA — OZMEP
Therapeutic areas
Omeprazole is registered in Infectious Disease (10 brands) and Gastroenterology (1 brand).
Sponsor landscape
Omeprazole is marketed by seven sponsors: Pharmacor, Medis Pharma, Alphapharm, Arrotex Pharmaceuticals, Southern Cross Pharma, and Boucher & Muir.
PBS and regulatory activity
One brand containing omeprazole has PBS-listed items, with a latest PBS schedule date of 1 May 2026. In the 2012–13 financial year, government expenditure on omeprazole was $37,214,704 across 2,107,257 prescriptions. The latest PBAC outcome was recorded on 1 November 2017, with one brand having PBAC outcomes on record. No AusPAR records are available for omeprazole.